Rocket Lab Stock: 7 Straight Red Days, Down 31%
Rocket Lab (RKLB) stock is on a 7-day losing streak, down 31.3% since the run began. That erased about $13.5 billion from the company’s market value, which now stands at about $29.6 billion. The stock closed at $45.42 on Friday, November 20, 69.8% below its 52-week high of $150.23 and 15.0% above its low of $39.48.

The Streak Next To The S&P 500
Returns for RKLB and the S&P 500 over the streak and the periods around it, all ending Friday, November 20 and including dividends:
| Return Period | RKLB | S&P 500 |
|---|---|---|
| 1 Day | -10.9% | -3.7% |
| 7 Days (Current Streak) | -31.3% | -9.2% |
| 1 Month (21 Trading Days) | -11.3% | -9.7% |
| 3 Months (63 Trading Days) | -33.5% | -9.5% |
| Year To Date | -34.9% | 2.0% |
| 1 Year (252 Trading Days) | 4.1% | 5.3% |
How The Streak Compares With The Market
Over the same 7 trading days, the S&P 500 returned -9.2% including dividends, so the slide is mostly Rocket Lab’s own story rather than the market’s. Over the past three months the stock is down 33.5%, a window that includes the streak; over the other 56 sessions of that window it was down 3.1%.
What The Numbers Say About The Slide
On the fundamentals, revenue grew 59.0% over the last twelve months, against a median of 8.5% for S&P 500 Industrials stocks; and its operating margin is -27.6%, versus a median of 17.5%. Rocket Lab does not have positive trailing earnings, so there is no meaningful price-to-earnings multiple to compare. The fundamentals give the sellers some support: an operating loss.
If the drop has you weighing an entry, resist buying on price alone. Our Buy the Dip screen ranks the marked-down names where growth and cash generation still hold up.
For anyone who would rather back the theme than one company, an aerospace & defense ETF like MISL holds the whole group, not just this stock. It is still a concentrated bet on one theme, which is the gap the portfolio below is built to close.
Weakness In One Name Should Be Noise, Not News
For a diversified holder, a streak like this is a data point. For a concentrated one, it is a hole in the plan. The difference is never the stock; it is the portfolio built around it.
Building that portfolio is what the Trefis High Quality (HQ) Portfolio does: roughly 30 businesses with the cash generation and balance-sheet strength to absorb a bad month, selected and rebalanced by rules. It has a track record of outpacing a benchmark that combines the S&P 500, the S&P MidCap 400, and the Russell 2000. Make the next streak, in either direction, someone else’s drama.